The complicated and labor-intensive manufacturing of novel cell and gene therapies requires efforts to improve workforce development programs for the nascent cell therapy industry broadly, and for cell manufacturing more specifically.
- Linda D. Ho
- Hadassah L. Robbins
- Aaron D. Levine